Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors

NCT05253131 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT05253131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05253131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Recruiting
Start date
August 4, 2026
Completion date
November 15, 2032
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mpnst, nf1, sarcoma